Simcere Pharmaceutical Group (SCR) Misses Q2 EPS by 2c

August 10, 2012 6:30 AM EDT Send to a Friend
Get Alerts SCR Hot Sheet
Trade SCR Now!
Join SI Premium – FREE
Simcere Pharmaceutical Group (NYSE: SCR) reported Q2 EPS of $0.08, $0.02 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $83.2 million versus the consensus estimate of $86.83 million.

For earnings history and earnings-related data on Simcere Pharmaceutical Group (SCR) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings

Add Your Comment